Skip to main content

Drug Interactions between Imlygic and tipiracil / trifluridine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

trifluridine talimogene laherparepvec

Applies to: tipiracil / trifluridine and Imlygic (talimogene laherparepvec)

If you are currently being treated or have recently been treated with trifluridine, you should let your doctor know before receiving talimogene laherparepvec. Depending on the dose and length of time you have been on trifluridine, you may be at risk for developing a potentially life-threatening herpes infection from exposure to talimogene laherparepvec. In some situations, your doctor may want to delay treatment with talimogene laherparepvec to give your body time to recover from the effects of trifluridine therapy. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

trifluridine food

Applies to: tipiracil / trifluridine

Trifluridine should be taken within one hour after eating your morning or evening meals. This may help to reduce the medication's harmful effects on white blood cells. Talk to you doctor or pharmacist if you have any questions or concerns.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer